0001213900-22-022364.txt : 20220428 0001213900-22-022364.hdr.sgml : 20220428 20220428170716 ACCESSION NUMBER: 0001213900-22-022364 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20220427 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220428 DATE AS OF CHANGE: 20220428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 180 Life Sciences Corp. CENTRAL INDEX KEY: 0001690080 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813832378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38105 FILM NUMBER: 22867910 BUSINESS ADDRESS: STREET 1: 830 MENLO AVENUE, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-507-0669 MAIL ADDRESS: STREET 1: 830 MENLO AVENUE, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: KBL MERGER CORP. IV DATE OF NAME CHANGE: 20161115 8-K 1 ea159003-8k_180lifescien.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 27, 2022

180 LIFE SCIENCES CORP.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-38105		90-1890354
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, CA

94306

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 507-0669

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ATNF		The NASDAQ Stock Market LLC
Warrants to purchase shares of Common Stock		ATNFW		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective on April 27, 2022, 180 Life Sciences Corp. (the “Company”, “we” and “us”)(directly or through an indirectly wholly-owned subsidiary) entered into (a) a First Amendment to Amended and Restated Employment Agreement with James N. Woody, M.D., Ph.D., the Chief Executive Officer and Director of the Company (the “First Woody Amendment”); (b) a First Amendment to Employment Agreement with Quan Anh Vu, the Chief Operating Officer and Chief Business Officer of the Company (the “First Vu Amendment”); (c) a First Amendment to Employment Agreement with Jonathan Rothbard, Ph.D., Chief Scientific Officer of the Company (“First Rothbard Amendment”); (d) a First Amendment to Employment Agreement with Sir Marc Feldmann, Ph.D., the Executive Co-Chairman of the Company Executive Co-Chairman, and the Chairman, CEO and Executive Director of CannBioRex Pharma Limited (“CannBioRex”), an indirect wholly-owned subsidiary of the Company (the “First Feldmann Amendment”); (e) a First Amendment to Consulting Agreement with Lawrence Steinman, M.D., the Executive Co-Chairman of the Company (the “First Steinman Amendment”); and (f) a Second Amendment to Consulting Agreement with Prof. Jagdeep Nanchahal, a consultant to the Company, a significant stockholder of the Company and the Chairman of our Clinical Advisory Board (the “Second Nanchahal Amendment”), which each amended the compensation agreements currently in place with such individuals.

Pursuant to the First Woody Amendment, First Vu Amendment and First Rothbard Amendment, each of Dr. Woody, Mr. Vu and Dr. Rothbard, agreed that effective January 1, 2022, their base salaries of $450,000, $390,000 and $375,000, respectively (their “Base Salaries”) (as provided for in their employment agreements) were amended to increase such amounts by 3% (the “Increase in Salary”) and effective March 1, 2022, their base salaries were reduced by 20% each ($92,700, $80,340 and $96,563, respectively) and that such reduced amounts (the “Accrued Amounts”) shall be accrued until such time as the Board of Directors determines that the Company has sufficient cash on hand to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”); and that $370,800, $321,360, and $289,688 of such base salaries, shall be payable per the payroll practices of the Company in cash by the Company to each of Dr. Woody, Mr. Vu and Dr. Rothbard, respectively, starting effective March 1, 2022 until the Funding Determination Date, and that on the Funding Determination Date, their salaries shall increase to the new base salary taking into account the Increase in Salary (with no accrual) ($463,500, $401,700 and $386,250, respectively) and the Accrued Amounts shall be paid by the Company, provided that in addition, at the discretion of the Board of the Directors, the base salaries on the Funding Determination Date of each executive may be further increased by 2%. Additionally, Mr. Rothbard agreed that any future increases to salary will be determined on an annual basis by the Company’s Board of Directors at the recommendation of the Compensation Committee, and the annual 10% increases provided in his agreement shall be overridden by such future determinations by the Board of Directors.

Pursuant to the First Feldmann Amendment and First Steinman Amendment, Prof. Sir Feldmann and Prof. Steinman agreed that effective March 1, 2022, their salary would be reduced by $225,000 (100%) and $56,250 (25%), respectively, and that such reduced amounts shall be accrued and paid on the Final Determination Date.

Pursuant to the Second Nanchahal Amendment, Prof. Nanchahal agreed that upon acceptance of the data for the phase 2b clinical trial for Dupuytren’s disease for publication (which occurred March 1, 2022, subject to editing and final approvals), his monthly fee was increased to £23,000, provided that £4,000 of such increase shall be accrued and £19,000 per month of such fees shall be payable per the payroll practices of the Company in cash by the Company starting effective March 1, 2022, and until the earlier of (a) November 1, 2022 or (b) the Funding Determination Date, at which time all accrued amounts shall be due.

The employment and consulting agreements with the individuals above are described in greater detail in the Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 28, 2022.

The foregoing descriptions of the First Woody Amendment, First Vu Amendment, First Rothbard Amendment, First Feldmann Amendment, First Steinman Amendment, and Second Nanchahal Amendment, do not purport to be complete and are qualified in their entirety by reference to the First Woody Amendment, First Vu Amendment, First Rothbard Amendment, First Feldmann Amendment, First Steinman Amendment, and Second Nanchahal Amendment, copies of which are attached as Exhibits 10.1 through Exhibit 10.6, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

10.1*		First Amendment to Amended and Restated Employment Agreement dated April 27, 2022, between 180 Life Sciences Corp. and James N. Woody, M.D., Ph.D.
10.2*		First Amendment to Employment Agreement dated April 27, 2022, between 180 Life Sciences Corp. and Quan Anh Vu
10.3*		First Amendment to Employment Agreement dated April 27, 2022, between 180 Life Sciences Corp. and Jonathan Rothbard, Ph.D.
10.4*		First Amendment to Employment Agreement dated April 27, 2022, between Cannbiorex Pharma Ltd. and Sir Marc Feldmann, Ph.D.
10.5*		First Amendment to Consulting Agreement dated April 27, 2022, between 180 Life Sciences Corp. and Lawrence Steinman, M.D.
10.6*		Second Amendment to Consulting Agreement dated April 27, 2022, between Cannbiorex Pharma Ltd. and Prof. Jagdeep Nanchahal

*	Filed herewith.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 28, 2022	180 LIFE SCIENCES CORP.

	By:	/s/ James N. Woody, M.D., Ph.D.
	Name:	James N. Woody, M.D., Ph.D.
	Title:	Chief Executive Officer

3

EX-10.1 2 ea159003ex10-1_180life.htm FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT DATED APRIL 27, 2022, BETWEEN 180 LIFE SCIENCES CORP. AND JAMES N. WOODY, M.D., PH.D

Exhibit 10.1

FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This First Amendment to Amended and Restated Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the “Company”), and James N. Woody (“Executive”) (collectively, the Company and Executive are the “Parties”).

WHEREAS, the Company and Executive have entered into an Amended and Restated Employment Agreement, dated made as of February 24, 2021, and effective November 6, 2020 (the “Agreement”)¹, concerning the employment of Executive as Chief Executive Officer of the Company;

WHEREAS, certain capitalized terms used below have the meanings given to such terms in the Agreement; and

WHEREAS, the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary basis.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged and confirmed, the parties hereto agree as follows:

1.

Effective January 1, 2022, the Base Salary of $450,000 is amended to increase such amount by 3% (the “Increase in Salary”) and effective March 1, 2022, the Base Salary is reduced by $92,700 (a 20% reduction) and such amounts (the “Accrued Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, whhas sufficient cash on hand to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”); and

2.

$370,800 of such Base Salary shall be payable per the payroll practices of the Company in cash by the Company starting effective March 1, 2022 until the Funding Determination Date

3.

On the Funding Determination Date, Executive’s salary shall increase to the Base Salary taking into account the Increase in Salary (with no accrual) and the Accrued Amounts shall be paid by the Company. In addition, at the discretion of the Board of the Directors, the Base Salary on the Funding Determination Date may be further increased by 2%.

4.

Except to the extent modified hereby, the Agreement shall remain in full force and effect.

5.

This Amendment shall be binding upon and inure to the benefit of the parties and their successors and assigns.

6.

This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

¹

https://www.sec.gov/Archives/edgar/data/1690080/000121390021013180/ea136864ex10-2_180lifesci.htm

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed as of the date and year first referenced above.

The “Company” 180 Life Sciences Corp.

Date: April 27, 2022 By: /s/ Ozan Pamir

Its: CFO

Printed Name:

Ozan Pamir

The “Executive”

Date: April 16, 2022 By: /s/ James N. Woody

James N. Woody

EX-10.2 3 ea159003ex10-2_180life.htm FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED APRIL 27, 2022, BETWEEN 180 LIFE SCIENCES CORP. AND QUAN ANH VU

Exhibit 10.2

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This First Amendment to Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the “Company”), and Quan Vu (“Executive”) (collectively, the Company and Executive are the “Parties”).

WHEREAS, the Company and Executive have entered into an Employment Agreement, dated October 29, 2021, and effective November 1, 2021 (the “Agreement”)¹, concerning the employment of Executive as Chief Operating Officer and Chief Business Officer of the Company;

WHEREAS, certain capitalized terms used below have the meanings given to such terms in the Agreement; and

WHEREAS, the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary basis.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged and confirmed, the parties hereto agree as follows:

1.

Effective January 1, 2022, the Base Salary of $390,000 is amended to increase such amount by 3% (the “Increase in Salary”) and effective March 1, 2022, the Base Salary is reduced by $80,340 (a 20% reduction) and such amounts (“Accrued Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”);

2.

$321,360 of such Base Salary shall be payable per the payroll practices of the Company in cash by the Company starting effective March 1, 2022 until the Funding Determination Date.

3.

On the Funding Determination Date, Executive’s salary shall increase to the Base Salary taking into account the Increase in Salary (with no accrual) and the Accrued Amounts shall be paid by the Company. In addition, at the discretion of the Board of the Directors, the Base Salary on the Funding Determination Date may be further increased by 2%.

4.

Except to the extent modified hereby, the Agreement shall remain in full force and effect.

5.

This Amendment shall be binding upon and inure to the benefit of the parties and their successors and assigns.

6.

This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

¹

https://www.sec.gov/Archives/edgar/data/0001690080/000121390021055978/ea149725ex10-1_180life.htm

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed as of the date and year first referenced above.

The “Company”	180 Life Sciences Corp.

Date: April 27, 2022	By:	/s/ Ozan Pamir
	Its:	CFO
	Printed Name:	Ozan Pamir

The “Executive”
Date: April 15, 2022	By:	/s/ Quan Vu
		Quan Vu

EX-10.3 4 ea159003ex10-3_180life.htm FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED APRIL 27, 2022, BETWEEN 180 LIFE SCIENCES CORP. AND JONATHAN ROTHBARD, PH.D

Exhibit 10.3

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This First Amendment to Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the “Company”), and Jonathan Rothbard (“Executive”) (collectively, the Company and Executive are the “Parties”).

WHEREAS, the Company and Executive have entered into an Employment Agreement, dated August 21, 2019, and effective November 6, 2020 (the “Agreement”)¹, concerning the employment of Executive as Chief Scientific Officer of the Company;

WHEREAS, certain capitalized terms used below have the meanings given to such terms in the Agreement; and

WHEREAS, the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary basis.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged and confirmed, the parties hereto agree as follows:

1.

Effective January 1, 2022, the Base Salary of $375,000 is amended to increase such amount by 3% (the “Increase in Salary”) and effective March 1, 2022, the Base Salary is reduced by $96,562.50 (a 25% reduction) and such amounts (“Accrued Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”);

2.

$289,687.50 of such Base Salary shall be payable per the payroll practices of the Company in cash by the Company starting effective March 1, 2022 until the Funding Determination Date.

3.

On the Funding Determination Date, Executive’s salary shall increase to the Base Salary taking into account the Increase in Salary (with no accrual) and the Accrued Amounts shall be paid by the Company. In addition, at the discretion of the Board of the Directors, the Base Salary on the Funding Determination Date may be further increased by 2%.

4.

Any future increases to salary will be determined on an annual basis by the Company’s board of directors at the recommendation of the Compensation Committee, and the annual 10% increases provided in the Agreement shall be overridden by such future determinations by the board of directors.

5.

Except to the extent modified hereby, the Agreement shall remain in full force and effect.

6.

This Amendment shall be binding upon and inure to the benefit of the parties and their successors and assigns.

7.

This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

¹	https://www.sec.gov/Archives/edgar/data/0001690080/000121390021036392/f10k2020ex10-44_180lifescien.htm

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed as of the date and year first referenced above.

The “Company”	180 Life Sciences Corp.

Date: April 27, 2022	By:	/s/ Ozan Pamir
	Its:	CFO
	Printed
	Name:	Ozan Pamir

The “Executive”
Date: April 15, 2022	By:	/s/ Jonathan Rothbard
		Jonathan Rothbard

EX-10.4 5 ea159003ex10-4_180life.htm FIRST AMENDMENT TO EMPLOYMENT AGREEMENT DATED APRIL 27, 2022, BETWEEN CANNBIOREX PHARMA LTD. AND SIR MARC FELDMANN, PH.D

Exhibit 10.4

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

This First Amendment to Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set forth below, is entered into by and between Cannbiorex Pharma Ltd., a UK corporation (the “CBR”) and a wholly owned subsidiary of 180 Life Sciences Corp. (“180 LS”, together with CBR, the “Company”), and Marc Feldmann (“Executive”) (collectively, the Company and Executive are the “Parties”).

WHEREAS, the Company and Executive have entered into an Employment Agreement, dated May 31, 2018, and effective November 6, 2020 (the “Agreement”), concerning the employment of Executive as Chief Executive Officer of CBR;

WHEREAS, the 180LS board of directors approved an increase in compensation to $225,000 per annum on November 16, 2021;

WHEREAS, certain capitalized terms used below have the meanings given to such terms in the Agreement; and

WHEREAS, the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary basis.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged and confirmed, the parties hereto agree as follows:

1.

Effective March 1, 2022, the Base Salary reduced by $225,000 (a 100% reduction) and such amounts (“Accrued Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”); and

2.

On the Funding Determination Date, the Accrued Amounts shall be paid by the Company.

3.

Except to the extent modified hereby, the Agreement shall remain in full force and effect.

4.

This Amendment shall be binding upon and inure to the benefit of the parties and their successors and assigns.

5.

This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed as of the date and year first referenced above.

The “Company”	180 Life Sciences Corp.

Date: April 27, 2022	By:	/s/ Ozan Pamir
	Its:	CFO
	Printed
	Name:	Ozan Pamir

	Cannbiorex Pharma Ltd

	By:	/s/ Ozan Pamir
	Its:	CFO
	Printed
	Name:	Ozan Pamir

The “Executive”
Date: April 28, 2022	By:	/s/ Marc Feldmann
		Marc Feldmann

EX-10.5 6 ea159003ex10-5_180life.htm FIRST AMENDMENT TO CONSULTING AGREEMENT DATED APRIL 27, 2022, BETWEEN 180 LIFE SCIENCES CORP. AND LAWRENCE STEINMAN, M.D

Exhibit 10.5

FIRST AMENDMENT TO CONSULTING AGREEMENT

This First Amendment to Consulting Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the “Company”), and Lawrence Steinman (“Executive”) (collectively, the Company and Executive are the “Parties”).

WHEREAS, the Company and Executive have entered into a Consulting Agreement, dated November 17, 2021, and effective November 1, 2021 (the “Agreement”)¹, concerning the engagement of Executive as Co-Chairman of the Company;

WHEREAS, certain capitalized terms used below have the meanings given to such terms in the Agreement; and

WHEREAS, the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary basis.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged and confirmed, the parties hereto agree as follows:

1.

Effective March 1, 2022, the Salary is reduced by $56,250 (a 25% reduction) and such amounts (“Accrued Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”); and

2.

On the Funding Determination Date, the Accrued Amounts shall be paid by the Company.

3.

Except to the extent modified hereby, the Agreement shall remain in full force and effect.

4.

This Amendment shall be binding upon and inure to the benefit of the parties and their successors and assigns.

5.

This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

¹	https://www.sec.gov/Archives/edgar/data/0001690080/000121390021060424/ea150938ex10-1_180lifesci.htm

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed as of the date and year first referenced above.

The “Company”	180 Life Sciences Corp.

Date: April 27, 2022	By:	/s/ Ozan Pamir
	Its:	CFO
	Printed Name:	Ozan Pamir

The “Executive”
Date: April 15, 2022	By:	/s/ Lawrence Steinman
		Lawrence Steinman

EX-10.6 7 ea159003ex10-6_180life.htm SECOND AMENDMENT TO CONSULTING AGREEMENT DATED APRIL 27, 2022, BETWEEN CANNBIOREX PHARMA LTD. AND PROF. JAGDEEP NANCHAHAL

Exhibit 10.6

SECOND AMENDMENT TO CONSULTING AGREEMENT

This Second Amendment to Consulting Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set forth below, is entered into by and between Cannbiorex Pharma Ltd., a UK corporation (the “Company”), and Jagdeep Nanchahal (“Consultant”) (collectively, the Company and Consultant are the “Parties”).

WHEREAS, the Company and the Consultant have entered into a First Amendment to Consultancy Agreement, dated March 31, 2021, and effective December 1, 2020 (the “Agreement”)¹, concerning the engagement of the Consultant as Chair of Clinical Advisory Board of 180 Life Sciences Corp.;

WHEREAS, certain capitalized terms used below have the meanings given to such terms in the Agreement; and

WHEREAS, the parties wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary basis.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged and confirmed, the parties hereto agree as follows:

1.

As outlined in the Agreement, upon acceptance of the data for the phase 2b clinical trial for Dupuytren’s disease for publication, the monthly fee of the Consultant is increased to £23,000. During the month of March 2022, the data for the phase 2b clinical trial for Dupuytren’s disease was accepted for publication, subject to editing and final approvals before an actual release date occurs. Therefore, the monthly fee was increased to £23,000, as of March 1, 2022 (the “Increase in Fees”), of which:

(a)

£4,000 of the amount of the Increase in Fees, payable per the regular payroll practices (the “Accrued Amounts”), shall be accrued until the earlier of (i) the Company raising a minimum of $15,000,000, or (ii) November 1, 2022 (the “Funding Determination Date”); and

(b)

£19,000 per month of such Fees shall be payable per the payroll practices of the Company in cash by the Company starting effective March 1, 2022 until the Funding Determination Date.

(c)

On the Funding Determination Date, the Accrued Amounts shall be paid by the Company.

2.

Except to the extent modified hereby, the Agreement shall remain in full force and effect.

3.

This Amendment shall be binding upon and inure to the benefit of the parties and their successors and assigns.

4.

This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

¹	https://www.sec.gov/Archives/edgar/data/0001690080/000121390021019967/ea138936ex10-2_180life.htm

IN WITNESS WHEREOF, the parties have caused the Amendment to be executed as of the date and year first referenced above.

The “Company”	Cannbiorex Pharma Ltd.

Date: April 27, 2022	By:	/s/ Ozan Pamir
	Its:	CFO
	Printed Name:	Ozan Pamir

The “Executive”
Date: April 27, 2022	By:	/s/ Jagdeep Nanchahal
		Jagdeep Nanchahal

EX-101.SCH 8 atnf-20220427.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 9 atnf-20220427_def.xml XBRL DEFINITION FILE EX-101.LAB 10 atnf-20220427_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.0001 per share Warrants to purchase shares of Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 11 atnf-20220427_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 27, 2022
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 27, 2022
Entity File Number	001-38105
Entity Registrant Name	180 LIFE SCIENCES CORP.
Entity Central Index Key	0001690080
Entity Tax Identification Number	90-1890354
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3000 El Camino Real
Entity Address, Address Line Two	Bldg. 4
Entity Address, Address Line Three	Suite 200
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94306
City Area Code	650
Local Phone Number	507-0669
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Common Stock, par value $0.0001 per share
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ATNF
Security Exchange Name	NASDAQ
Warrants to purchase shares of Common Stock
Title of 12(b) Security	Warrants to purchase shares of Common Stock
Trading Symbol	ATNFW
Security Exchange Name	NASDAQ

XML 13 ea159003-8k_180lifescien_htm.xml IDEA: XBRL DOCUMENT 0001690080 2022-04-27 2022-04-27 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2022-04-27 2022-04-27 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2022-04-27 2022-04-27 iso4217:USD shares iso4217:USD shares 0001690080 false 8-K 2022-04-27 180 LIFE SCIENCES CORP. DE 001-38105 90-1890354 3000 El Camino Real Bldg. 4 Suite 200 Palo Alto CA 94306 650 507-0669 false false false false Common Stock, par value $0.0001 per share ATNF NASDAQ Warrants to purchase shares of Common Stock ATNFW NASDAQ true false EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 3 25 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://180lifesciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea159003-8k_180lifescien.htm atnf-20220427.xsd atnf-20220427_def.xml atnf-20220427_lab.xml atnf-20220427_pre.xml ea159003ex10-1_180life.htm ea159003ex10-2_180life.htm ea159003ex10-3_180life.htm ea159003ex10-4_180life.htm ea159003ex10-5_180life.htm ea159003ex10-6_180life.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea159003-8k_180lifescien.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "atnf-20220427_def.xml" ] }, "inline": { "local": [ "ea159003-8k_180lifescien.htm" ] }, "labelLink": { "local": [ "atnf-20220427_lab.xml" ] }, "presentationLink": { "local": [ "atnf-20220427_pre.xml" ] }, "schema": { "local": [ "atnf-20220427.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 2, "memberStandard": 0, "nsprefix": "ATNF", "nsuri": "http://180lifesciences.com/20220427", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea159003-8k_180lifescien.htm", "contextRef": "From2022-04-27to2022-04-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://180lifesciences.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea159003-8k_180lifescien.htm", "contextRef": "From2022-04-27to2022-04-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "ATNF_CommonStockParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001 per share" } } }, "localname": "CommonStockParValue0.0001PerShareMember", "nsuri": "http://180lifesciences.com/20220427", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "domainItemType" }, "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of Common Stock" } } }, "localname": "WarrantsToPurchaseSharesOfCommonStockMember", "nsuri": "http://180lifesciences.com/20220427", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://180lifesciences.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 20 0001213900-22-022364-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-022364-xbrl.zip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end